# Table of Contents

*Declaration* i  
*Preface* ii  
*Acknowledgements* iv  
*Dedication* vi  
List of Abbreviations vii  
List of Figures x  
List of Tables xi  
List of Schemes xii  
Table of Contents xiii

## CHAPTER-I

1. Introduction 1  
   1.1. Metabolic syndrome 1  
   1.2. Diabetes 1  
      1.2.1. Types of diabetes 2  
         1.2.1.1. Type 1 diabetes mellitus (T1DM) 3  
         1.2.1.2. Type 2 diabetes mellitus (T2DM) 4  
         1.2.1.3. Gestational diabetes mellitus (GDM) 4  
   1.3. Pathogenesis of T2DM 5  
   1.4. Current & Newer therapies for the treatment of T2DM 6  
      1.4.1. Current therapies for the treatment of T2DM 6  
         1.4.1.1. Injectable therapies for the treatment of T2DM 6  
         1.4.1.2. Oral antidiabetic agents for the treatment of T2DM 9  
      1.4.2. Newer therapies for the treatment of T2DM 12  
   1.5. Introduction to Dipeptidyl Peptidase IV (DPP-IV) inhibitors 18
1.5.1. DPP-IV and their importance 18
1.5.2. Dipeptidyl peptidase family 20
1.5.3. Role of DPP-IV in metabolic diseases 22

1.6. Crystal structure of DPP-IV 24

1.7. Molecular recognition of ligands in DPP-IV 28

1.8. Mechanism of action of DPP-IV inhibitors 32

1.9. Challenges in developing potent and selective DPP-IV inhibitors 32

1.10. Overview on DPP-IV inhibitors under recent development 33

1.11. Introduction to Cytochrome P450 (CYPs) and its importance 36

1.12. Conclusion 37

CHAPTER-II

2. Design Strategy of DPP-IV inhibitors 38

2.1. Orally active, potent and selective DPP-IV inhibitors 38

2.1.1. Rational for designing cyanopyrrolidine containing peptidomimetic based DPP-IV inhibitors. (First series) 41

2.1.2. Rational for designing peptidomimetic based DPP-IV inhibitors, devoid of CYP liabilities. (Second series) 42

2.1.3. Rational for designing aminomethylpiperidone based DPP-IV inhibitors. (Third series) 44

2.1.4. Conclusion 46

CHAPTER-III

3. Results and discussion 47

3.1. Cyanopyrrolidine containing peptidomimetic based DPP-IV inhibitors (First series) 48

3.1.1. Chemistry 48
3.1.2. *In vitro* DPP-IV inhibitory activity, selectivity and structure activity relationship (SAR) 52

3.1.3. *In vivo* antidiabetic activity of selected compounds (17c and 17d) 56

3.1.4. Pharmacokinetic (PK) studies of selected compounds (17c and 17d) 57

3.1.5. Molecular docking study of peptidomimetic 17c 58

3.1.6. Conclusion 60

3.2. Peptidomimetic based DPP-IV inhibitors, devoid of CYP liabilities (Second series) 60

3.2.1. Chemistry 60

3.2.2. *In vitro* DPP-IV inhibitory activity, selectivity and structure activity relationship (SAR) 67

3.2.3. *In vitro* CYP inhibition study of selected peptidomimetics 70

3.2.4. Molecular docking study of lead peptidomimetic 34m 70

3.2.5. Conclusion 72

3.3. Aminomethylpiperidone based DPP-IV inhibitors (Third series) 73

3.3.1. Chemistry 73

3.3.2. *In vitro* DPP-IV inhibitory activity, selectivity and structure activity relationship (SAR) 79

3.3.3. *In vitro* CYP inhibition study of aminomethyl-pipyridone 68v. 82

3.3.4. *In vivo* antidiabetic activity of aminomethyl-pipyridone 68v. 82

3.3.5. Pharmacokinetic (PK) studies of aminomethyl-pipyridone 68v 84

3.3.6. Molecular docking study of aminomethyl-pipyridone 68v 85

3.3.7. Conclusion 86
CHAPTER-IV

4. Overall summary and Future prospects 87
   4.1. Overall summary of current investigation 87
   4.2. Future Plan 90

CHAPTER-V

5. Experimental 92
   5.1. Chemistry 92
      5.1.1. Materials and Methods 92
      5.1.2. Experimental Details 93
   5.2. Biology 202
      5.2.1. DPP-IV inhibitory activity and selectivity over other serine protease (in vitro) 202
      5.2.2. CYP inhibition study (in vitro) 203
      5.2.3. Pharmacodinemic study (Antidiabetic activity) (in vivo) 203
   5.3. Pharmacokinetic study (PK study) 204
   5.4. Docking study 204

6. Spectral Data 205
   (ESI-MS, HPLC, \(^1\)H-NMR & \(^{13}\)C-NMR of representative compounds)

7. References 293

8. Publications 309

9. Vitae 328